



PROFICIENCY TESTING REPORT
ISHTM-AIIMS EXTERNAL QUALITY ASSURANCE PROGRAMME
 NABL accredited program as per ISO/IEC 17043:2010 standard
 Organized By Department of Hematology, AIIMS, New Delhi-110029

Duration of stability testing - minimum upto 8 days at ambient temp. after dispatch of specimens

EQAP CODE No. : 3919

Distribution No.: 161-K

Month/Year: October/2023

Instrument ID: HORIBA

Model Name.: YUMIZEN H550

Serial No.: 207YAXH03883

Name & Contact No. of PT Co-ordinator: Dr. Manoranjan Mahapatra (Prof. & Head), Hematology, AIIMS, Delhi,
 Tel: 9013085730 , E-Mail : accuracy2000@gmail.com

Date of issue & status of the report: 29-01-2024[Final].

CBC and Retic Assessment

Test Parameters	S.No.	Among Lab (Accuracy Testing)						Within Lab (Precision Testing)			
		Your Result 1	Your Result 2	Your Results Sum of 2 Value	Consensus result sum of 2 values (Assigned Value)	Uncertainty of Assigned Values	Z Score	Yours Results Diff. of 2 Values	Consensus Result Diff. of 2 values (Assigned Value)	Uncertainty of Assigned Values	Z Score
WBC x10 ³ /µl	1	2.86	0.54	3.4	7.7	0.043	-4.14	2.32	0.1	0.006	24.96
RBC x10 ⁶ /µl	1	4.71	4.69	9.4	9.43	0.010	-0.11	0.02	0.05	0.003	-0.58
Hb g/dl	1	14.2	14.2	28.4	28.4	0.030	0.00	0	0.1	0.008	-0.67
HCT%	1	43.9	43.6	87.5	86.05	0.190	0.30	0.3	0.5	0.028	-0.45
MCV-fl	1	93.2	92.2	185.4	183	0.333	0.28	1	0.2	0.023	2.70
MCH-Pg	1	30.4	30.2	60.6	60.2	0.070	0.25	0.2	0.2	0.017	0.00
MCHC-g/dl	1	32.7	32.4	65.1	66	0.145	-0.25	0.3	0.3	0.020	0.00
Plt. x10 ³ /µl	1	106	98	204	255.5	2.060	-1.00	8	5	0.396	0.51
Retic %	2	1.9	0.5	2.4	15	0.317	-1.43	1.4	0.4	0.027	1.69

P.S . Assesment

YOUR REPORT			CONSENSUS REPORT		
DLC%	3	Nrbcs=00 , Poly=77 L=17, E=01, Mono/Promono=05 , B1=00 P.M.=00, Mye=00, Meta=00, Other=00	Poly: 73-80 , Lympho: 15-22 , Mono: 2-4, Eosino: 1-2 , Blast/Promyelo/Myelo/Meta: 0-5		
RBC Morphology	3	ANISOPOIKILOCYTOSIS (+), NORMOCYTIC TO MACROCYTIC RBC. TEAR DROP CELLS AND TARGET CELLS NOTED. POLYCHROMATOPHILS SEEN.	Predominantly: Normocytic/Normochromic; Moderate: Anisocytosis, Poikilocytosis , Target cells , tear drop cells		
Diagnosis	3	00	Sickle cell-Beta Thalassemia		

COMBINED DATA VALUES OF TOTAL PARTICIPANTS

Test parameters	S.No.	Total participants covered in the current dist. 161--K	Total No. responded	% of Labs with Z Score 0-2		% of Labs with Z Score 2-3		% of Labs with Z Score >3	
				Among labs	Within lab	Among labs	Within lab	Among labs	Within lab
WBC x10³/µl	1	272	269	84.01	89.96	3.35	4.83	12.64	5.21
RBC x10⁶/µl	1	272	272	83.46	94.49	6.25	1.84	10.29	3.67
Hb g/dl	1	272	272	88.24	89.71	6.62	3.68	5.14	6.61
HCT%	1	272	268	92.54	93.28	4.48	3.73	2.98	2.99
MCV-fl	1	272	268	93.28	88.43	4.85	7.46	1.87	4.11
MCH-Pg	1	272	268	87.69	92.54	7.84	4.48	4.47	2.98
MCHC-g/dl	1	272	268	91.42	91.04	5.97	4.85	2.61	4.11
Plt. x10³/µl	1	272	268	92.91	88.81	5.97	6.34	1.12	4.85
ReticCount%	2	272	224	94.64	89.73	3.57	7.14	1.79	3.13
PS Assessment	3	272	208	Satisfactory :88.98%, Borderline Sat. :3.30%, Unsatisfactory :7.72%					

***Comments:**

1). **Among Lab (EQA) : CBC result for WBC unacceptable, may be due to random/human error.PS Diagnosis not reported, remaining results acceptable.**

2). **Within Lab (IQA) : Difference in the CBC measurement values for WBC unacceptable, may be due to random/human error.**

Note-1: EQA (External Quality Assurance) : Your Performance among various of participating labs in PT, to determine the accuracy of your results.

IQA (Internal Quality Assurance) : Your Performance of comparison of two consecutive measurement values within your lab to test the precision of your autoanalyzer.

Note-2: Z score among & within lab were calculated, as per to ISO/IEC 13528:2015 standard. Z score among lab (EQA)= (Your Result Sum of two values - Consensus Result sum of two values)/(Normalised IQR)

Z score within lab (IQA)= (Your Result Difference of two values - Consensus Result difference of two values)/(Normalised IQR)

IQR = Quartile 3 - Quartile 1 of participant data, Normalised IQR = 0.7413 x IQR

Note-3: Z score 0 to ±2: Acceptable, Z score ±2 to ±3 :Warning Signal, Z score > ±3 : Unacceptable [As per ISO/IEC 13528:2015 standard]

Note-4: Z score value between“0 to ±2” are texted in green colour. Z score value between“±2 to ±3” are texted in orange colour. Z score value > ±3 are texted in red colour.

Note-5: Homogeneity and stability testing of PT sample were done as per ISO 13528:2015 standard. To pass homogeneity test, between sample SD (Ss) should be smaller than the check value (0.3*SDPA). To pass the stability test, average difference in measurement values of first and last day sample ($\bar{x}-\bar{y}$) should be smaller than the check value (0.3*SDPA).

Note-6: ISHTM-AIIMS-EQAP does not subcontract any task of its scheme

Note-7: Participants are free to use methods/analyzer of their own choice.

Note-8: Proficiency testing (PT) samples are sent quarterly to each participant.

Note-9: All the necessary details regarding design and implementation of PT, are provided in the instruction sheet as well as on programme's website www.ishtmaiimseqap.com.

Note 10: Reports are kept confidential.

Report authorized by,



Dr. Manoranjan Mahapatra (Prof. & Head)

PT Co-ordinator: ISHTM-AIIMS-EQAP

Department of Hematology, AIIMS, New Delhi

-----End Of Report-----

Patient Information	Specimen Information	Client/Doctor Information
Name : Mrs.ANJU NATANI	Visit ID : LNNG442	Client Code : PUP2937
Age/Gender : 60 Y 0 M 0 D /Female	Collected : 16/Feb/2024 07:48	Client Name : PUP SHRI JI DIAGNOSTICS
MobileNo :	Received : 16/Feb/2024 12:39	Client Add. : MATA MANDIR
UHID : LDAA01567941	Reported : 16/Feb/2024 15:26	Client No. : 9340658151
Address :	IP/OP/Barcode :	Ref Doctor : Dr.SELF
	Report Status : Final Report	

Test Name	Result	Bio. Ref. Range	Unit	Method
-----------	--------	-----------------	------	--------

Complete Blood Count (CBC) , WHOLE BLOOD EDTA

Hemoglobin (Hb)	11.3	12-15	g/dL	Spectrophotometry
Red Blood Cell (RBC) Count	3.48	3.8-4.8	Million/cu.mm	Impedence
Packed Cell Volume (PCV) / Hematocrit	34.7	36-46	%	Calculated
Mean Corpuscular Volume (MCV)	99.8	83-101	fL	Calculated
Mean Corpuscular Hemoglobin (MCH)	32.6	27-32	pg	Calculated
Mean Corpuscular Hb Concentration (MCHC)	32.6	31.5-34.5	g/dL	Calculated
Red Cell Distribution Width (RDW)	13.6	11.6-14	%	Calculated
Total Leucocyte Count (TLC)	5,800	4000-10000	Cells/cu.mm	Impedence
Differential Leucocyte Count (DLC)				
Neutrophils	60.0	40-80	%	Impedence & FCM
Lymphocytes	34.0	20-40	%	Impedence & FCM
Monocytes	4.0	2-10	%	Impedence & FCM
Eosinophils	2.0	1-6	%	Impedence & FCM
Basophils	0.0	<1-2	%	Impedence & FCM
Absolute Leucocyte Count				
Neutrophils	3,480	2000-7000	Cells/cu.mm	Calculated
Lymphocytes	1,972	1000-3000	Cells/cu.mm	Calculated
Monocytes	232	200-1000	Cells/cu.mm	Calculated
Eosinophils	116	20-500	Cells/cu.mm	Calculated
Platelet Count	207,000	150000-410000	per cu.mm	Impedence
Mean Platelet Volume (MPV)	14.1	7.4-12.0	fL	Impedence

*** End Of Report ***

Dr. Priyanka Saxena

Dr. Priyanka Saxena
MD (Pathologist)
Consultant Pathologist

Page 1 of 1



SIN No:HA00651318

This test has been performed at Lupin Diagnostics Laboratory, DL BHOPAL E-5/48 Ground Floor Srp Arcade Arera Near Vandematram Square, ARERA, BHOPAL , 462016

TWBC DLC



JLC

Results

Run Date 02/17/2024 10:41:53 AM
 Last Name
 First Name
 Gender
 Patient ID
 Birth Date
 Sample comments


Operator LUPIN
 Sample ID HA00651318
 Rack/Pos
 Department
 Physician
 Type Standard

				Range
RBC	3.49	L	10 ³ /μL	3.80 - 6.00
HGB	11.3	I	g/dL	11.5 - 17.0
HCT	33.9	I	%	35.0 - 52.0
MCV	97.1		μm ³	76.0 - 100.0
MCH	32.3		pg	27.0 - 34.0
MCHC	33.3		g/dL	32.0 - 35.0
RDW-CV	13.7		%	11.0 - 17.0
RDW-SD	55.4	H	μm ³	37.0 - 49.0
PLT	235	*	10 ³ /μL	150 - 400
PCT	0.32	*	%	0.15 - 0.40
MPV	13.6	H*	μm ³	8.0 - 11.0
PDW	33.8	H*	μm ³	11.0 - 22.0
P-LCC	138		10 ³ /μL	44 - 140
P-LCR	58.7	h	%	18.0 - 50.0



Recommended actions
 Slide review
Alarms
 Control solution expired
 PLT
 RBC PLT Interference
Susp. Pathologies
 Macroplatelets
 PLT aggregate ?
 Malaria P. vivax ?

WBC	5.48	10 ³ /μL	Range	3.50 - 10.00
NEU	3.11	#	Range	%
LYM	1.81		1.60 - 7.00	57.0
MON	0.40		1.00 - 3.00	33.2
EOS	0.11		0.20 - 0.80	7.3
BAS	0.03		0.00 - 0.50	2.0
LIC	0.02		0.00 - 0.15	0.5
			0.00 - 0.10	0.3



Slide Review

- | | | |
|-----------------|---------------|-----------------|
| utrophil | Myeloblast | Anisocytosis |
| mphocyte | Promyelocyte | Hypochromia |
| ocyte | Myelocyte | Polychromasia |
| inophil | Metamyelocyte | Poikilocytosis |
| ophil | Blast | Microcytosis |
| ical Lymphocyte | Target Cell | Macrocytosis |
| r | Sickle Cell | Platelet Clumps |

Reviewed on _____ by _____ Signature :

Reference Laboratory- Lupin Diagnostics, NRL

Date of study conducted- 17.02.2024


Sr No	Parameters	Sample-1			Reference range
		Mrs. Anju Natani			
		NRL	DL Bhopal	%Diff	
1	RBC	3.49	3.48	0.29	3.8-6
2	HB	11.3	11.3	0.00	11.5-17
3	PCV	33.9	34.7	-2.33	35-52
4	MCV	97.1	99.8	-2.74	76-100
5	MCH	32.3	32.6	-0.92	27-34
6	MCHC	33.3	32.6	2.12	32-35
7	RDWCV	13.7	13.6	0.73	11.0-17
8	RDWSD	55.4	52.9	4.62	37-49
9	PLT	235	207	12.67	150-400
10	PCT	0.32	0.29	9.84	0.15-0.40
11	MPV	13.6	14.1	-3.61	8.0-11
12	PDW	33.8	36.1	-6.58	11.0-22
13	PLCC	138	131	5.20	44-140
14	PLCR	58.7	63.3	-7.54	18-50
15	WBC	5.48	5.8	-5.67	3.5-10
16	NEUT	3.11	3.37	-8.02	1.6-7
17	LYMP	1.81	1.99	-9.47	1.0-3
18	MONO	0.4	0.22	58.06	0.2-0.8
19	EOS	0.11	0.15	-30.77	0.0-0.50
20	BASO	0.03	0.0	200.0	0.0-0.15
21	LIC	0.02	0.02	0.00	0.0-0.10
22	NEUT%	57	57.7	-1.22	40-73
23	LYM%	33.2	33.9	-2.09	15-45
24	MONO%	7.3	3.8	63.06	4.0-12
25	EOS%	2	2.5	-22.22	0.5-7
26	BASO%	0.5	0.0	200.0	0.0-2.0
27	LIC	0.3	0.3	0.00	0.0-0.10

Observations-

- ✓ >80% Clinical correlation noted in samples.
- ✓ High % Difference noted due to statistical limitations.

Conclusion:

Based on obtained result recovery Inter laboratory comparison study successfully passed for CBC test parameter.


Documented By
(Mr. Manish Patel)

Approved by
(Dr. Priyanka S)

Title	PT/ EQAS EVALUATION RECORD
Document Number	FRM.QCM.03
Version	02
Amendment No	00
Effective Date	02.06.2023



Date of Investigation: 17/02/24

PT/EQAS Set Identification:	AIIMS EQAS 161-K
Date of PT/EQAS:	Oct-2023
Acceptable/ Unacceptable Results	TWBC
Acceptable Result Range:	$\pm 7.7 - \pm 0.006$
Previous Trends/ Unacceptable Results from this Analyte/ Test:	no
Classification of Problems: (Please tick) Clerical:	<input type="checkbox"/> Transcription error (may be pre- or post-analytical factors) <input type="checkbox"/> Wrong method has been registered for analysis or method change not updated.
Details of Investigation:	no
Methodological	<input type="checkbox"/> Instrument function checks (e.g., temperatures, blank readings, pressures) not performed as necessary, or results not within acceptable range. <input type="checkbox"/> Scheduled instrument maintenance not performed appropriately. <input type="checkbox"/> Incorrect instrument calibration. <input type="checkbox"/> Standards or reagents improperly reconstituted and stored, or inadvertently used beyond expiration date. <input type="checkbox"/> Instrument probes misaligned. <input type="checkbox"/> Problem with instrument data processing functions. The laboratory may need to contact the manufacturer to evaluate such problems. <input type="checkbox"/> Problem in manufacture of reagents / standards, or with instrument settings specified by manufacturer <input type="checkbox"/> Carry-over from previous specimen. <input type="checkbox"/> Automatic pipettor not calibrated to acceptable precision and accuracy. <input type="checkbox"/> Imprecision from result being close to detection limit of method. <input type="checkbox"/> QC material not run within expiration date, or improperly stored.

Title	PT/ EQAS EVALUATION RECORD
Document Number	FRM.QCM.03
Version	02
Amendment No	00
Effective Date	02.06.2023



- QC material not run at relevant analyte concentration.
- Result not within reportable range (linearity) for instrument / reagent system.
- Obstruction of instrument tubing / orifice by clot or protein.
- Incorrect incubation times.

Details of Investigation:

NO

Technical

- EQA material improperly reconstituted.
- Testing delayed after reconstitution of EQA material (with problem from evaporation or deterioration).
- Sample not placed in proper order on instrument.
- Result released despite unacceptable QC data.
- QC data within acceptable limits but showed trend suggestive of problem with the assay.
- Inappropriate quality control limits / rules. If the acceptable QC range is too wide, the probability increases that a result will fall within the acceptable QC range yet exceed acceptable limits for EQA.
- Manual pipetting / diluting performed inaccurately, at an incorrect temperature or with incorrect diluent.
- Calculation error or result reported using too few significant digits.
- Secondary specimen tubes incorrectly labeled.
- In addition to above discipline specific errors may also occur

Details of Investigation:

NO

Problem with PT/EQAS Material

- Matrix effects: The performance of some instrument / method combinations may be affected by the matrix of the PT/EQAS sample. This can be overcome to some extent by assessing participants in peer groups – to be done by the PT/EQAS provider.
- Non-homogenous test material due to variability in fill volumes, inadequate mixing, or inconsistent heating of lyophilized specimens.
- Non-viable samples for microbiology PT/EQAS program.
- Haemolysis on an immune-haematology program samples.

Details of Investigation:

Title	PT/ EQAS EVALUATION RECORD
Document Number	FRM.QCM.03
Version	02
Amendment No	00
Effective Date	02.06.2023



Problem with PT/EQAS Evaluation

- Peer group not appropriate.
- Inappropriate target value: Target values developed from participant consensus can be inappropriate from non-homogeneous testing material or lingering ("masked") outliers. However, occasional inappropriate target values occur in every PT program. Inappropriate evaluation interval: An evaluation interval may be inappropriately narrow e.g. if ± 2 standard deviation units are used with an extremely precise method; the acceptable range may be much narrower than needed for clinical usefulness.
- Incorrect data entry by PT provider.

Details of Investigation:

NO

No Explanation: Attributed to Random Error

Any Others (explain)

Summary of Investigation:

NO any deviation in IAC performance. NO any issue with respect to reagent, analyser, previous EQAS performance within a acceptable range.

Was patient data affected? & Corrective action taken if Patient data was affected.

NO

Corrective/ Preventive action taken to prevent Reoccurrence

performance of RWBC parameters closely monitor in next sample.

Title	PT/ EQAS EVALUATION RECORD
Document Number	FRM.QCM.03
Version	02
Amendment No	00
Effective Date	02.06.2023



Conclusions <i>Based on above findings concluded unacceptable performance due to transitional or sample performance monitor closely in next cycle.</i>	
Quality Manager/ Team Leader <i>Manish</i>	Date: <i>17/02/24</i>
Lab Head <i>[Signature]</i>	Date: <i>17/02/24</i>

Controlled Copy